4Manori S, Suzuki F, Hosaka T, et al. Interferonmonotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commence-ment of treatment. Gastroenterology,2004,39:776-782.
5Becon BR. Treatment of patients with hepatitis C and normal serum aminotransferase level. Hepatology ,2002,36 (5 Suppl) : S179-184.
6Okanou E,Makiyam AA,Nakayama M,et al. Afollow-up study to determine the value of liver biospyand need for anti-viral therapy for hepatitis C carrierswith persistently normal serum aminotransferase. J Hepatol, 2005,43:5994505.
4Strader DB, Wright T, Thomas DL, et al. Diagnosis management and treatment of hepatitis C[J].Hepatology, 2004, 39 (4): 1147-1171.
5Reichard O, Norkrans G, Fryden A, et al. Randomised double blind, placebo-controlled trial of interferonα2b with and without rihavirin for chronic hepatitis C [J].Lancet, 1998, 351 (2): 83-87.
6Barbaro G, Di Lorenzo G, Soldini M, et al, Evaluation of long-term efficacy of interferon alpha2b and ribavirin in combination in nave patients with chronic hepatitis C: an Italian multicenter experience [J]. J Hepatol, 2000, 33 (3): 448-455.
7Fried MW, Hadziyannis SJ. Treatment of chronic hepatitis C infection with peg interferons plus ribavirin [J]. Semin Liver Dis, 2004, 24 (Suppl2): 47-54.
8YuML, Dai CY, Huang JF, et al. Rapid virological responseand treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial [J]. Hepatology, 2008, 47 ( 6): 1884-1893.
9Ferenei P, Laferl H, Scherzer TM, et al. A randomized, prospective trial of ribavirin 400 rag/day versus 800 mg/day in combination with peg interferon alfa-2a in hepatitis C virus genotypes2 and 3 [J]. Hepatology, 2008, 47 (6): 1816- 1823.
10Ferenci P, Brunner H, Laferl H, et al.Randomized comparison of 12 or 24 weeks of peg interferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2 /3 infection [J]. Hepatology, 2008, 47 (6) : 1837-1845.
4Imazeki F, Yokosuka O, Fukai K, et al. Prevalence of diabetes mellitus and insulin resistance in patientswith chronic hepatitis C : comparison with hepatitis B virus-infected and hepatitis C virus cleared patients. Liver Int ,2008,28:355-362.
5Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chro- nic hepatitis C:association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology ,2008,134:416-423.
6Chu CJ,Lee SD, Hung TH,et al. Insulin resistance is a major determi- nant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin. Aliment 29 Pharmacol Ther,2009 ,1:46-54.
7Kawaguchi Y, Mizuta T, Oza N, et al. Eradication of hepatitis C virus by interferon improves whole-body insulin resistance and hyperinsulinae- mia in patients with chronic hepatitis C. Liver Int,2009,29:871-877.
8Chu CJ,Lee SD,Hung TH,et al.Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin.Alimentary Pharmacology and Therapeutics,2009,11:46-54.
9Gehring S,Gregory SH,Kuzushita N ,et al.Type 1 interferon augments DNA-based vaccination against hepatitis C virus core protein [J].J Med Virol, 2005,75 (2) : 249-257.
10Wolber EM,Haase B ,Jelkmann W.Thrombopoietin production in human hepatic cell cultures (HepG2) is resistant to IFN-alpha,IFN-beta, and IFN-gamma treatment[J]. J Interferon Cytokine Res,2002,22(12) : 1185-1189.
